An estimated 60% of patients with Alzheimer's disease develop epilepsy or subclinical epileptiform activity over the course of the disease. New-onset seizures in cognitively healthy adults also ...

Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe ...

MOG antibody-associated disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a ...

MOG Antibody-associated Disease (MOGAD) is a rare autoimmune disease of the central nervous system. The blood of patients contains antibodies against myelin oligodendrocyte glycoprotein (MOG), a ...

Just like the moment a mosquito bites, the shot of dengue virus I received in my arm was so quick and painless that afterward I wasn't even sure it happened at all. A few years ago, I wrote a story ...

Abstract: Inspired by the enhanced perception mechanism of raptor vision in various hunting environments, we propose a biological raptor vision perception enhancement algorithm for Unmanned Aerial ...

GOSSELIES, Belgium and NANTES, France, Nov. 12, 2025 /PRNewswire/ -- AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. When Laura Ehrlich gave birth to her ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. Scientists have made monumental ...

This article is part of “Innovations In: RSV,” an editorially independent special report that was produced with financial support from MSD, Sanofi and AstraZeneca. When Laura Ehrlich gave birth to her ...

Andembry is the first monthly Factor XIIa inhibitor for the prevention of HAE attacks and will be available to patients “before the end of June,” CSL announced. The FDA on Tuesday signed off on CSL’s ...

Amivantamab targets EGFR and MET receptors, offering a novel approach for mCRC treatment, especially in RAS and BRAF wild-type patients. The OrigAMI-2 study compares amivantamab with standard ...